#ESMO18: Novartis claims a key win in breast cancer with PI3K drug alpelisib
MUNICH — PI3K inhibitors have had their problems over the years, failing some studies, proving to be disappointing in terms of durability in others. But Novartis $NVS believes it may have come up with part of the answer with its latest data on BYL719 (alpelisib) in combination with fulvestrant.
Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progression-free survival times for patients, hitting 11 months compared to 5.7 months for a control arm treated only with fulvestrant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.